Therefore, the risk conferred by APOE-ε4 and p.E318G carriers in familial AD (OR = 16.4, 95% CI = 5.6–48.2, p = 5.8×10−8) compared to the control group was higher than the risk associated with sporadic AD (OR = 10.1, 95% CI = 4.8–20.9, p = 9.0×10−12). Here, APOE is linked to Alzheimer disease.